Search research articles
Contact Us
Filters
Showing results (11-20 of 466) with videos related to
Page
of 47
Sort By:
The Journal of Infectious Diseases
|
February 2, 2011
Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity
Jason Grebely, Gregory J Dore
Hepatology (Baltimore, Md.)
|
April 28, 2007
Low incidence of HCV reinfection: exposure, testing frequency, or protective immunity?
Gregory J Dore, Joanne Micallef
Antiviral Research
|
January 29, 2014
Can hepatitis C virus infection be eradicated in people who inject drugs?
Jason Grebely, Gregory J Dore
Seminars in Liver Disease
|
December 23, 2011
What is killing people with hepatitis C virus infection?
Jason Grebely, Gregory J Dore
The New England Journal of Medicine
|
August 14, 2020
People with Hepatitis C Who Inject Drugs - Underserved, Not Undeserving
Gregory J Dore, Stacey Trooskin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 9, 2016
Editorial Commentary: Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World" Outcomes
Marianne Martinello, Gregory J Dore
Infectious Disease Clinics of North America
|
May 21, 2018
Elimination of Hepatitis C Virus in Australia: Laying the Foundation
Gregory J Dore, Behzad Hajarizadeh
Journal of Hepatology
|
April 16, 2017
Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030
Gregory J Dore, Jason Grebely
Hepatology (Baltimore, Md.)
|
December 6, 2011
An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community
Jason Grebely, Gregory J Dore
Nature Reviews. Gastroenterology & Hepatology
|
December 2, 2010
Hepatitis C: Enhancing treatment for hepatitis C among drug users
Jason Grebely, Gregory J Dore
Page
of 47
Search research articles
Search
Showing results (11-20 of 466) with videos related to
Sort By:
Page
of 47
The Journal of Infectious Diseases
|
February 2, 2011
Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity
Jason Grebely, Gregory J Dore
Hepatology (Baltimore, Md.)
|
April 28, 2007
Low incidence of HCV reinfection: exposure, testing frequency, or protective immunity?
Gregory J Dore, Joanne Micallef
Antiviral Research
|
January 29, 2014
Can hepatitis C virus infection be eradicated in people who inject drugs?
Jason Grebely, Gregory J Dore
Seminars in Liver Disease
|
December 23, 2011
What is killing people with hepatitis C virus infection?
Jason Grebely, Gregory J Dore
The New England Journal of Medicine
|
August 14, 2020
People with Hepatitis C Who Inject Drugs - Underserved, Not Undeserving
Gregory J Dore, Stacey Trooskin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 9, 2016
Editorial Commentary: Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World" Outcomes
Marianne Martinello, Gregory J Dore
Infectious Disease Clinics of North America
|
May 21, 2018
Elimination of Hepatitis C Virus in Australia: Laying the Foundation
Gregory J Dore, Behzad Hajarizadeh
Journal of Hepatology
|
April 16, 2017
Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030
Gregory J Dore, Jason Grebely
Hepatology (Baltimore, Md.)
|
December 6, 2011
An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community
Jason Grebely, Gregory J Dore
Nature Reviews. Gastroenterology & Hepatology
|
December 2, 2010
Hepatitis C: Enhancing treatment for hepatitis C among drug users
Jason Grebely, Gregory J Dore
Page
of 47